RLMD — Relmada Therapeutics Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapValue Trap

Annual balance sheet for Relmada Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	—	—	—	—	—
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	117	212	148	96.3	44.9
Net Total Receivables	0.079	0.086	0.512	0	—
Prepaid Expenses
Total Current Assets	118	223	153	97.5	45.8
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	0.001	0	—	—	—
Long Term Notes Receivable
Other Long Term Assets
Total Assets	118	223	153	97.6	45.8
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Total Current Liabilities	12.6	15.1	12.5	12.2	10.3
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	12.6	15.1	12.5	12.2	10.3
Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Total Equity	106	208	140	85.4	35.5
Total Liabilities & Shareholders' Equity	118	223	153	97.6	45.8
Total Common Shares Outstanding